Drug profile · INN
regorafenib
STIVARGA
regorafenib (STIVARGA) is a fibroblast growth factor receptor 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — regorafenib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 1
- Programs
- 21
- Data quality
- 0.84
Quick answer
regorafenib (STIVARGA) is a fibroblast growth factor receptor 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Fibroblast growth factor receptor 2 inhibitor
Primary target: Discoidin domain-containing receptor 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is regorafenib?
regorafenib (STIVARGA) is a fibroblast growth factor receptor 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for regorafenib?
STIVARGA is a marketed brand name for regorafenib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of regorafenib?
regorafenib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.